Document is current
Any future updates will be listed below
-
Authors
Elmarakeby, Haitham A. https://orcid.org/0000-0002-4315-4347
Hwang, Justin https://orcid.org/0000-0003-1686-7103
Arafeh, Rand
Crowdis, Jett
Gang, Sydney
Liu, David
AlDubayan, Saud H.
Salari, Keyan
Kregel, Steven
Richter, Camden
Arnoff, Taylor E.
Park, Jihye
Hahn, William C. https://orcid.org/0000-0003-2840-9791
Van Allen, Eliezer M. https://orcid.org/0000-0002-0201-4444
- License Information
-
More Information
Article History
Received: 6 November 2020
Accepted: 17 August 2021
First Online: 22 September 2021
Competing interests
: W.C.H. is a consultant for Thermo Fisher, Solasta Ventures, iTeos, Frontier Medicines, Tyra Biosciences, MPM Capital, KSQ Therapeutics and Parexel and is a founder of KSQ Therapeutics. E.M.V. is a consultant/advisor for Tango Therapeutics, Genome Medical, Invitae, Enara Bio, Janssen, Manifold Bio and Monte Rosa Therapeutics. E.M.V. receives research support from Novartis and BMS. The other authors declare no competing interests.
